Concepedia

Author

Ralph Tiedt

Novartis (Switzerland)ORCID

Also Known As

R Tiedt, R. Tiedt, Ralph Tiedt

92

Publications

7.9K

Citations

29

H-Index

58

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical ResearchUniversity Hospital of BaselNovartis (China)Novartis (United States)
RT

About

Ralph Tiedt is an author at Novartis (Switzerland) specializing in medicine, cell biology, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

16

1.4K

2

Natural Sciences

4

4

218

3

Engineering

2

2

701

4

Health Sciences

1

1

133

5

Biochemistry

1

1

66

Ralph Tiedt

×

36

Publications

7.8K

Citations

27

H-Index

YearCitations

A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders

Róbert Královics, Francesco Passamonti, Andreas Buser,

New England Journal of Medicine

2005

3.4K

Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

E. Robert McDonald, Antoine de Weck, Michael R. Schlabach,

Cell

2017

687

Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu,

Cancer Discovery

2016

527

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

Ralph Tiedt, Hui Hao-Shen, Marta Sobas,

Blood

2007

430

Pf4-Cre transgenic mice allow the generation of lineage-restricted gene knockouts for studying megakaryocyte and platelet function in vivo

Ralph Tiedt, Tibor Schomber, Hui Hao-Shen,

Blood

2006

409

Talin is required for integrin-mediated platelet function in hemostasis and thrombosis

Brian G. Petrich, Patrizia Marchese, Zaverio M. Ruggeri,

The Journal of Experimental Medicine

2007

300

Megakaryocyte-restricted MYH9 inactivation dramatically affects hemostasis while preserving platelet aggregation and secretion

Catherine Léon, Anita Eckly, Béatrice Hechler,

Blood

2007

179

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2

Róbert Královics, Soon-Siong Teo, Andreas Buser,

Blood

2005

177

Capmatinib (INC280) Is Active Against Models of Non–Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation

Sabrina Baltschukat, Barbara Schacher Engstler, Alan Huang,

Clinical Cancer Research

2019

171

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition

Oliver Weigert, Andrew A. Lane, Liat Bird,

The Journal of Experimental Medicine

2012

161

Page 1